In Novosibirsk, mutation screening of patients with hypercholesterolemia is currently conducted by targeted sequencing of several genes involved in the development of monogenic FH (i.e., LDLR, APOB, PCSK9, and LDLRAP1). This evidence concerns the gene LDLR and familial hyperaldosteronism.